老年冠状动脉疾病患者的药物洗脱支架(SENIOR):随机单盲试验
SENIOR为随机单盲试验,纳入9国44中心≥75岁、稳定心绞痛、无症状缺血或急性冠脉综合征且至少一支冠脉狭窄≥70%(左主干≥50%)适合PCI的患者,排除需CABG、不能耐受DAPT、预期寿命<1年、既往出血性卒中、阿司匹林或P2Y12抑制剂过敏/禁忌、无症状缺血左心肌<10%且FFR≥0.80者。记录预定DAPT时长(稳定1个月、不稳定6个月)后1:1随机分配至药物洗脱支架或相似金属裸支架,患者盲法。1年主要终点(全因死亡、心肌梗死、卒中或缺血驱动靶病变血运重建复合)在DES组68例(12%)vs BMS组98例(16%),RR 0.71(95%CI 0.52-0.94),p=0.02。出血并发症26例(5%)vs 29例(5%),RR 0.90(0.51-1.54),p=0.68;支架血栓3例(1%)vs 8例(1%),RR 0.38(0.00-1.48),p=0.13。作者认为DES联合短程类BMS的DAPT方案对行PCI的老年患者是有吸引力的选择。
要点
- ≥75岁行PCI患者,DES组1年主要不良心脑血管事件12% vs BMS组16%,RR 0.71(95%CI 0.52-0.94),p=0.02。
- DAPT时长按预定记录:稳定表现1个月,不稳定表现6个月,两组疗程相似。
- 1年出血并发症DES组5% vs BMS组5%,RR 0.90(95%CI 0.51-1.54),p=0.68,无显著差异。
- 1年支架血栓DES组1% vs BMS组1%,RR 0.38(95%CI 0.00-1.48),p=0.13,无显著差异。
- 作者认为DES联合短程类BMS的DAPT方案对行PCI的老年患者是有吸引力的选择。
适用人群与场景
- 年龄≥75岁,有稳定心绞痛、无症状缺血或急性冠脉综合征,且至少一支冠脉狭窄≥70%(左主干≥50%)认为适合经皮冠状动脉介入治疗(PCI)的患者。
- 排除:需冠状动脉旁路移植术血运重建者;不能耐受、获得或依从DAPT者;需额外手术者;非心脏合并症预期寿命<1年者;既往出血性卒中者;阿司匹林或P2Y12抑制剂过敏者;P2Y12抑制剂禁忌者;无症状缺血左心肌<10%且血流储备分数≥0.80者。
诊断标准与关键阈值
- 冠脉狭窄标准:至少一支冠脉狭窄≥70%,左主干狭窄≥50%,认为适合PCI。
- 无症状缺血排除标准:左心肌缺血<10%且血流储备分数≥0.80。
处置流程与药物剂量
- 记录预定DAPT时长:稳定表现患者1个月,不稳定表现患者6个月。
- 按1:1随机分配至药物洗脱支架(DES)或相似金属裸支架(BMS),单盲(患者盲法),评估结局者盲法。
- 随机化由中央计算机系统完成,采用区组随机(区组大小2、4、8或16),按中心和抗血小板药物分层。
- 主要终点评估时间:30天、180天和1年。
研究设计与关键结果
- 随机单盲试验,纳入9国44中心,2014年5月21日至2016年4月16日随机分配1200例患者:DES组596例(50%),BMS组604例(50%)。
- 1年主要终点(全因死亡、心肌梗死、卒中或缺血驱动靶病变血运重建复合)DES组68例(12%)vs BMS组98例(16%),RR 0.71(95%CI 0.52-0.94),p=0.02。
- 1年出血并发症DES组26例(5%)vs BMS组29例(5%),RR 0.90(95%CI 0.51-1.54),p=0.68。
- 1年支架血栓DES组3例(1%)vs BMS组8例(1%),RR 0.38(95%CI 0.00-1.48),p=0.13。
证据类型、等级与局限
- 证据类型:随机单盲试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于≥75岁适合PCI的患者,DES联合短程DAPT较BMS联合相似疗程DAPT可降低1年主要不良心脑血管事件。
- 作者认为DES联合短程类BMS的DAPT方案对行PCI的老年患者是有吸引力的选择。
指南或共识出处
- SENIOR试验,ClinicalTrials.gov注册号NCT02099617,由Boston Scientific资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Elderly patients regularly receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of double antiplatelet therapy (DAPT). The aim of this study was to compare outcomes between these two types of stents with a short duration of DAPT in such patients.
METHODS: In this randomised single-blind trial, we recruited patients from 44 centres in nine countries. Patients were eligible if they were aged 75 years or older; had stable angina, silent ischaemia, or an acute coronary syndrome; and had at least one coronary artery with a stenosis of at least 70% (≥50% for the left main stem) deemed eligible for percutaneous coronary intervention (PCI). Exclusion criteria were indication for myocardial revascularisation by coronary artery bypass grafting; inability to tolerate, obtain, or comply with DAPT; requirement for additional surgery; non-cardiac comorbidities with a life expectancy of less than 1 year; previous haemorrhagic stroke; allergy to aspirin or P2Y12 inhibitors; contraindication to P2Y12 inhibitors; and silent ischaemia of less than 10% of the left myocardium with a fractional flow reserve of 0·80 or higher. After the intended duration of DAPT was recorded (1 month for patients with stable presentation and 6 months for those with unstable presentation), patients were randomly allocated (1:1) by a central computer system (blocking used with randomly selected block sizes [two, four, eight, or 16]; stratified by site and antiplatelet agent) to either a DES or similar BMS in a single-blind fashion (ie, patients were masked), but those assessing outcomes were masked. The primary outcome was to compare major adverse cardiac and cerebrovascular events (ie, a composite of all-cause mortality, myocardial infarction, stroke, or ischaemia-driven target lesion revascularisation) between groups at 1 year in the intention-to-treat population, assessed at 30 days, 180 days, and 1 year. This trial is registered with ClinicalTrials.gov, number NCT02099617.
FINDINGS: Between May 21, 2014, and April 16, 2016, we randomly assigned 1200 patients (596 [50%] to the DES group and 604 [50%] to the BMS group). The primary endpoint occurred in 68 (12%) patients in the DES group and 98 (16%) in the BMS group (relative risk [RR] 0·71 [95% CI 0·52-0·94]; p=0·02). Bleeding complications (26 [5%] in the DES group vs 29 [5%] in the BMS group; RR 0·90 [0·51-1·54]; p=0·68) and stent thrombosis (three [1%] vs eight [1%]; RR 0·38 [0·00-1·48]; p=0·13) at 1 year were infrequent in both groups.
INTERPRETATION: Among elderly patients who have PCI, a DES and a short duration of DAPT are better than BMS and a similar duration of DAPT with respect to the occurrence of all-cause mortality, myocardial infarction, stroke, and ischaemia-driven target lesion revascularisation. A strategy of combination of a DES to reduce the risk of subsequent repeat revascularisations with a short BMS-like DAPT regimen to reduce the risk of bleeding event is an attractive option for elderly patients who have PCI.
FUNDING: Boston Scientific.
参考来源
- Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2017. PMID: 29102362. doi:10.1016/S0140-6736(17)32713-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。